TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26264446

Group type: EXPERIMENTAL
Intervention: Opportunistic breast cancer screening (clinical breast examination and referral for mammographic screening)
Number of subjects: 7436

Group type: COMPARATOR
Intervention: Usual care (no explicit instruction for breast screening or mammography referrals)
Number of subjects: 7436

Group type: EXPERIMENTAL
Intervention: Opportunistic breast cancer screening
Number of subjects: 7436

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7436
Study: 24235073

Group type: EXPERIMENTAL
Intervention: High-efficiency on-line haemodiafiltration (HDF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-flux haemodialysis (HD)
Number of subjects: 42
Study: 22383266

Group type: EXPERIMENTAL
Intervention: Bergamot essential oil inhalation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard supportive care (Control)
Number of subjects: 37
Study: 20174583

Group type: EXPERIMENTAL
Intervention: Cosmed K4b(2) portable metabolic analyzer
Number of subjects: 19

Group type: COMPARATOR
Intervention: Medgraphics D‐Series stationary gas exchange system
Number of subjects: 19
Study: 18525391

Group type: EXPERIMENTAL
Intervention: Combined endurance training (ET)/Resistance training (RT) for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Endurance training (ET) alone for 12 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both ET/RT and ET groups
Number of subjects: 38
Study: 15877554

Group type: EXPERIMENTAL
Intervention: NITE-AD intervention (sleep hygiene education, daily walking, increased light exposure)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NITE-AD intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (general dementia education and caregiver support)
Number of subjects: 36
Study: 12700935

Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia (MUA) with intra-articular normal saline injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manipulation under anaesthesia (MUA) alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manipulation under anaesthesia (MUA) with intra-articular methylprednisolone injection
Number of subjects: 100
Study: 10472779

Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate) at a daily total dose of 500 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate)
Number of subjects: 90
Study: 8758107

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg, Isoniazid 400 mg, and Pyrazinamide 1.25 g daily for 3 months
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 1765317

Group type: EXPERIMENTAL
Intervention: 10 mg nalbuphine
Number of subjects: 137

Group type: COMPARATOR
Intervention: 50 mg pethidine
Number of subjects: 137
Study: 6751144

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intramuscular regime
Number of subjects: 20
Study: 31145388

Group type: EXPERIMENTAL
Intervention: Maximal isometric fatiguing exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Submaximal isometric fatiguing exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Submaximal intermittent isometric contractions
Number of subjects: 20
Study: 30450637

Group type: EXPERIMENTAL
Intervention: 3K3A-APC at 540 μg/kg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 28320473

Group type: EXPERIMENTAL
Intervention: VIPP-SD Twins (5 home visits in a 3-month period)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dummy intervention
Number of subjects: 100
Study: 26477023

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy and relaxation treatment (SHE treatment)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 73
Study: 23639598

Group type: EXPERIMENTAL
Intervention: RM-131 (100 μg, subcutaneously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21062115

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) 100 U
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 29
Study: 19116919

Group type: EXPERIMENTAL
Intervention: Active corner inflammatory lesion (CIL) on MRI
Number of subjects: 29

Group type: COMPARATOR
Intervention: No active inflammation on MRI
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Resolved CIL after anti-TNF treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Inflammation on baseline MRI
Number of subjects: 29

Group type: COMPARATOR
Intervention: No inflammation on baseline MRI
Number of subjects: 29
Study: 17606024

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current indications for CPAP
Number of subjects: 0
Study: 15141043

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery
Number of subjects: 872

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 872
Study: 11212971

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg daily for 2 weeks, then 100 mg daily for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine 30 mg daily for 2 weeks, then 60 mg daily for 4 weeks
Number of subjects: 16
Study: 11189192

Group type: EXPERIMENTAL
Intervention: Taileqi troches
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 100
Study: 8086844

Group type: EXPERIMENTAL
Intervention: Workshop on medical ethics for family medicine preceptors
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group of preceptors not invited to the workshop
Number of subjects: 68
Study: 2584586

Group type: EXPERIMENTAL
Intervention: Spherical soft contact lenses
Number of subjects: 16
Study: 4556011

Group type: EXPERIMENTAL
Intervention: 4-chlorotestosterone acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28888614

Group type: EXPERIMENTAL
Intervention: Curricular intervention group (IG)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 181
Study: 26807967

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Real-time adherence monitoring
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both SMS reminders and real-time monitoring
Number of subjects: 62
Study: 25011982

Group type: EXPERIMENTAL
Intervention: Flutamide treatment (GD50F)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flutamide treatment (GD90F)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Flutamide treatment (GD108F)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (nontreated pigs)
Number of subjects: 3
Study: 22236137

Group type: EXPERIMENTAL
Intervention: olanzapine-LAI 210 mg/2 weeks
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: olanzapine-LAI 300 mg/2 weeks
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: olanzapine-LAI 405 mg/4 weeks
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: combined olanzapine-LAI group
Number of subjects: 404

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 404
Study: 20028447

Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer (ANL) applied once every 2 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Amorolfine nail lacquer (ANL)
Number of subjects: 52
Study: 19192855

Group type: EXPERIMENTAL
Intervention: Induction period attendance
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Employment-based reinforcement of cocaine abstinence
Number of subjects: 111
Study: 15999461

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lacidipine
Number of subjects: 59
Study: 11313303

Group type: EXPERIMENTAL
Intervention: ISIS‐2302
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9141002

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine 40 micrograms
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hepatitis B vaccine 20 micrograms
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rHuIL‐2 administration (500,000 U)
Number of subjects: 40
Study: 7951643

Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 8
Study: 3663463

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desethylamiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 0
Study: 2667437

Group type: EXPERIMENTAL
Intervention: Total Gastrectomy (TG)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Subtotal Gastrectomy (SG)
Number of subjects: 169
Study: 31647032

Group type: EXPERIMENTAL
Intervention: Fast-track multidisciplinary treatment (FTMDT) with fast-track perioperative treatment and XELOX adjuvant chemotherapy
Number of subjects: 342

Group type: COMPARATOR
Intervention: Conventional treatment with conventional perioperative treatment and mFOLFOX6 adjuvant chemotherapy
Number of subjects: 342
Study: 29133641

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT) in trabeculectomy augmented with Mitomycin C (MMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) augmented trabeculectomy (Control group)
Number of subjects: 40
Study: 25643024

Group type: EXPERIMENTAL
Intervention: Adolescents discounting money at intake
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Adults discounting money at intake
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Adults discounting cannabis over treatment
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Adolescents discounting cannabis over treatment
Number of subjects: 269
Study: 23594450

Group type: EXPERIMENTAL
Intervention: Actual electroacupuncture
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham acupuncture (Control)
Number of subjects: 86
Study: 21667729

Group type: EXPERIMENTAL
Intervention: Palmar plating with locking screws
Number of subjects: 40

Group type: COMPARATOR
Intervention: Percutaneous K-wire fixation
Number of subjects: 40
Study: 19828211

Group type: EXPERIMENTAL
Intervention: Pramiconazole (200 mg taken once, and 200 mg taken once daily for 2 or 3 days)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 17093160

Group type: EXPERIMENTAL
Intervention: Methionine intake of 5.8 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methionine intake of 7.3 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Methionine intake of 12.9 mg . kg(‐1) . d(‐1) without dietary cysteine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Methionine intake of 17.2 mg . kg(‐1) . d(‐1) without dietary cysteine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cysteine-sparing effect
Number of subjects: 6
Study: 15897725

Group type: EXPERIMENTAL
Intervention: intensive psychosocial relapse‐prevention program + anxiety treatment program (CBT + optional SSRI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: intensive psychosocial relapse‐prevention program alone
Number of subjects: 96
Study: 11529375

Group type: EXPERIMENTAL
Intervention: Conventional phototherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no phototherapy)
Number of subjects: 80
Study: 9663809

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) iontophoresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) iontophoresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-N(G)-monomethyl-arginine (L-NMMA) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noradrenaline infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin administration
Number of subjects: 0
Study: 7831064

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg tablet bid)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mesoglycan (24 mg tablet bid)
Number of subjects: 44
Study: 3343933

Group type: EXPERIMENTAL
Intervention: APM-sweetened beverage (10 mg APM/kg body weight per serving)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-sweetened beverage
Number of subjects: 8
Study: 31808785

Group type: EXPERIMENTAL
Intervention: Comparative frame (news article emphasizing comparative rates of opioid mortality among whites compared to blacks)
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: Absolute frame (news article emphasizing absolute rates of opioid mortality among whites)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Control group (no news article)
Number of subjects: 1549
Study: 30717711

Group type: EXPERIMENTAL
Intervention: Univariable predictors of depression outcome
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Univariable predictors of adverse effects on HADS-D depression score
Number of subjects: 570

Group type: COMPARATOR
Intervention: Comparison between study arms
Number of subjects: 570
Study: 28633089

Group type: EXPERIMENTAL
Intervention: Pmab-FOLFOX4
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pmab-FOLFIRI
Number of subjects: 77
Study: 26297704

Group type: EXPERIMENTAL
Intervention: Walking session at 60-75% of heart rate reserve
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control rest
Number of subjects: 34
Study: 24498810

Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide 40 mg intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: Atropine 0.5 mg intravenously
Number of subjects: 120
Study: 21258894

Group type: EXPERIMENTAL
Intervention: Chinese drugs for supporting essence and strengthening Pi (SESP)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy + SESP
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 146
Study: 19692062

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with a loading dose of 0.25% bupivacaine or 0.2% ropivacaine, followed by continuous drip 0.2% ropivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nonepidural analgesia with intraoperative morphine and postoperative oxycodone or tramadol plus ibuprofen or paracetamol for 48 hours
Number of subjects: 45
Study: 17005508

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: No inhaled anaesthetics
Number of subjects: 100
Study: 12883662

Group type: EXPERIMENTAL
Intervention: High TS expression
Number of subjects: 229

Group type: COMPARATOR
Intervention: Low TS expression
Number of subjects: 229
Study: 11387782

Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure of 15 mmHg to 10 mmHg during laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9239455

Group type: EXPERIMENTAL
Intervention: Granular formulation of lornoxicam (8 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard tablets of lornoxicam (8 mg)
Number of subjects: 18
Study: 8513660

Group type: EXPERIMENTAL
Intervention: Computerized pharmacokinetic program for adjusting theophylline infusion rates
Number of subjects: 35

Group type: COMPARATOR
Intervention: Empiric physician adjustments
Number of subjects: 35
Study: 3441775

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29899015

Group type: EXPERIMENTAL
Intervention: Incentive arm with personalized step goals and daily feedback for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received no other interventions
Number of subjects: 0
Study: 26519995

Group type: EXPERIMENTAL
Intervention: Adjustable ultrafiltration (AUF)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Adjustable intravenous loop diuretics (ALD)
Number of subjects: 224
Study: 25516327

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted 24-hour recall
Number of subjects: 110

Group type: COMPARATOR
Intervention: Written record-assisted method
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Beverage screener
Number of subjects: 110
Study: 22518376

Group type: EXPERIMENTAL
Intervention: Provisional abutment (PA) group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Definitive abutment (DA) group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between PA and DA groups
Number of subjects: 28
Study: 20070389

Group type: EXPERIMENTAL
Intervention: User-designed Medicaid managed care (MMC) guidebook; 77% of intervention participants reported using the guidebook, with 97.9% finding it somewhat or very useful.
Number of subjects: 692

Group type: COMPARATOR
Intervention: Control group (no guidebook intervention).
Number of subjects: 692
Study: 18091257

Group type: EXPERIMENTAL
Intervention: Chronic subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 38
Study: 16274302

Group type: EXPERIMENTAL
Intervention: Modified tunnel technique
Number of subjects: 31

Group type: COMPARATOR
Intervention: Langer and Langer technique
Number of subjects: 31
Study: 12372124

Group type: EXPERIMENTAL
Intervention: rBet v 1 trimer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: rBet v 1 fragments
Number of subjects: 10

Group type: COMPARATOR
Intervention: rBet v 1 wild-type
Number of subjects: 10

Group type: COMPARATOR
Intervention: diluent (albumin)
Number of subjects: 10
Study: 10449884

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Aspirin with thrombolytic treatment
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Aspirin without thrombolytic treatment
Number of subjects: 753
Study: 8580215

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Modified porcine surfactant (Curosurf)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both surfactants
Number of subjects: 12
Study: 1688487

Group type: EXPERIMENTAL
Intervention: 75 mg of AOAA four times a day for 1 week
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 318978

Group type: EXPERIMENTAL
Intervention: Amoxycillin (500 mg, three times a day for 10 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Co-trimoxazole (up to 480 mg trimethoprim and 2,400 mg sulphamethoxazole daily for males, two thirds of this dose for females)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 100
Study: 30017152

Group type: EXPERIMENTAL
Intervention: Lava digital scan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: iTero digital scan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerec digital scan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 10
Study: 28797783

Group type: EXPERIMENTAL
Intervention: tbo-filgrastim (Granix) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Number of subjects: 97

Group type: COMPARATOR
Intervention: filgrastim (Neupogen) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: tbo-filgrastim (Granix)
Number of subjects: 97

Group type: COMPARATOR
Intervention: filgrastim (Neupogen)
Number of subjects: 97
Study: 26694073

Group type: EXPERIMENTAL
Intervention: Self-reported leisure time physical activity (LTPA)
Number of subjects: 2367

Group type: EXPERIMENTAL
Intervention: Slight physical activity up to 4 hours a week in men with IGT
Number of subjects: 2367

Group type: EXPERIMENTAL
Intervention: More intense physical activity in men with IGT
Number of subjects: 2367
Study: 25247957

Group type: EXPERIMENTAL
Intervention: Chiari I malformation patients with transverse sinus stenosis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chiari I malformation patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 22323041

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist condition (WLC)
Number of subjects: 32
Study: 20381664

Group type: EXPERIMENTAL
Intervention: Rhythm control (64% of patients)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Rate control (36% of patients)
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (first prescriptions)
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (second prescriptions)
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 1461
Study: 18928074

Group type: EXPERIMENTAL
Intervention: Mental illness role-play as part of routine teaching
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (no role-play)
Number of subjects: 332
Study: 15982121

Group type: EXPERIMENTAL
Intervention: Low-level timing (isochronous tapping)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sequencing of multiple targets (rhythm production)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Selection against a dominant rhythm and switching between rhythms
Number of subjects: 32
Study: 12056785

Group type: EXPERIMENTAL
Intervention: 20% alanyl-glutamine infusion of 0.5 g/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10491061

Group type: EXPERIMENTAL
Intervention: Cooling micrografts at 1 degrees C for 5 hours (experimental group B)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Room temperature preservation at 26 degrees C for 5 hours (control group A)
Number of subjects: 10
Study: 8776210

Group type: EXPERIMENTAL
Intervention: Menstrual Cycle Triggered Training (MCTT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular Training (RT)
Number of subjects: 0
Study: 1730080

Group type: EXPERIMENTAL
Intervention: A + I (cytarabine 100 mg/m2/d + idarubicin 13 mg/m2/d)
Number of subjects: 214

Group type: COMPARATOR
Intervention: A + D (cytarabine 100 mg/m2/d + daunorubicin 45 mg/m2/d)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: A + I
Number of subjects: 214

Group type: COMPARATOR
Intervention: A + D
Number of subjects: 214